Ozempic Linked to Lower Psychiatric Hospitalization Risk
A large Swedish study finds semaglutide, the drug in Ozempic and Wegovy, is associated with a 21% lower risk of psychiatric hospitalization in people with
People with bipolar disorder taking the drug semaglutide had a 21% lower risk of psychiatric hospitalization. This finding comes from a Griffith University study of nearly 15,000 Swedish patients over 15 years.
Semaglutide is the active ingredient in the diabetes and weight-loss medications Ozempic and Wegovy. It belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1RAs). Researchers analyzed nationwide data to see if these drugs, already established for metabolic conditions, had any link to psychiatric outcomes in bipolar disorder.
Study Details and Key Finding
Led by Professor Mark Taylor, the team examined Swedish health records from 2009 to 2024. They focused on periods when patients were prescribed a GLP-1 medication versus when they were not.
"People with bipolar disorder who were taking semaglutide had significantly lower rates of psychiatric hospitalization," Professor Taylor said. The specific reduction in risk was 21%. The research was published in the journal Acta Psychiatrica Scandinavica.
Not All GLP-1 Drugs Showed Benefit
The mental health benefit appeared specific to semaglutide. Other GLP-1 medications studied did not show the same protective association.
The study found no reduced risk of hospitalization linked to the drugs liraglutide or dulaglutide. This suggests the potential psychiatric benefit may not apply to the entire drug class.
Potential Biological Mechanisms
Researchers theorize the effect may stem from semaglutide's impact on brain biology. GLP-1 signaling could help protect the brain by reducing inflammation and cellular stress. These processes are often associated with bipolar disorder.
Stabilizing these biological pathways might contribute to greater mood stability. This could, in turn, lower the risk of a severe relapse requiring hospital care. Diabetes, obesity, and bipolar disorder frequently co-occur and may share some underlying mechanisms.
A Call for Further Research
The findings are observational, meaning they show a link but cannot prove semaglutide causes the reduced hospitalization risk. Professor Taylor stated he hopes the results will now be examined in a randomized controlled trial.
Such a trial would provide stronger evidence about whether semaglutide itself can improve psychiatric outcomes. The World Health Organization estimates roughly 37 million people worldwide live with bipolar disorder. The study adds to growing evidence that GLP-1 drugs may have benefits extending beyond their original uses.
